Valuation: ChitogenX Inc.

Market Cap 831K 604K 517K 482K 442K 57.75M 848K 5.72M 2.23M 28.94M 2.27M 2.22M 95.81M P/E 2023
-2.01x
P/E 2024 -3.99x
Enterprise Value 4.67M 3.39M 2.9M 2.71M 2.49M 325M 4.76M 32.14M 12.53M 163M 12.73M 12.46M 538M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
100%
Yield 2023 *
-
Yield 2024 -
3 years 0
Extreme 0
0.14
5 years 0
Extreme 0
0.6
10 years 0
Extreme 0
1
Manager TitleAgeSince
Chief Executive Officer 65 2024-02-27
Director of Finance/CFO 62 2018-09-17
Chief Tech/Sci/R&D Officer 68 -
Director TitleAgeSince
Chairman 67 2019-03-05
Chairman 65 2016-07-25
Chairman 65 -
Date Insider Type Main position Quantity % Market Cap.
11/19/24 Buy

Chief Financial Officer

710,000 0.8541%
7/17/24 Option

Chief Executive Officer

544,400 0.6549%
7/17/24 Option

General Counsel

100,000 0.1203%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-96.43% 302K
-0.07%+3.98%+3.17%+24.49% 51.22B
-1.36%+4.82%+485.55%+614.84% 45.38B
-2.04%+3.69%+19.34%+91.23% 41.97B
+2.72%+6.02%+33.33%+19.66% 42.15B
0.00%-3.91%+18.49%+47.98% 31.95B
-1.85%+3.48% - - 16.73B
+0.72%+5.27%+31.55%+145.37% 17.1B
-0.69%+2.61%+6.29%+34.45% 14.76B
+0.50%+3.62%+82.64%+46.53% 13.91B
Average -0.21%+2.91%+75.60%+103.12% 27.52B
Weighted average by Cap. -0.21%+3.18%+103.65%+150.86%

Financials

2023 2024
Net sales - -
Net income -6.23M -4.52M -3.87M -3.61M -3.32M -433M -6.35M -42.86M -16.71M -217M -16.98M -16.61M -718M -1.55M -1.13M -966K -901K -827K -108M -1.58M -10.69M -4.17M -54.1M -4.24M -4.14M -179M
Net Debt 6.21M 4.51M 3.86M 3.6M 3.3M 431M 6.33M 42.7M 16.65M 216M 16.92M 16.55M 715M 3.84M 2.79M 2.39M 2.23M 2.04M 267M 3.92M 26.42M 10.3M 134M 10.47M 10.24M 443M
Logo ChitogenX Inc.
ChitogenX Inc. is a Canada-based clinical-stage regenerative medicine company. The Company is engaged in the development of therapeutic tissue repair technologies to improve tissue healing. The Company is committed to the clinical development of its proprietary RESTORE technology platform, a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC), to enhance healing in various musculoskeletal conditions. Ortho-R, its lead Chitosan-PRP hybrid biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, and cartilage such as the meniscus. Its other formulations are being developed to leverage the technology's performance characteristics, such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease.
Employees
-

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CHGX Stock